Catherine Bollard
Directeur/Membre du Conseil chez CABALETTA BIO, INC.
Fortune : 7 480 $ au 30/06/2024
Profil
Catherine Bollard is the founder of Mana Therapeutics, Inc. She currently holds multiple positions including Program Director at Children's National Hospital, Director at Alliance for Regenerative Medicine, Independent Director at Cabaletta Bio, Inc., and Professor at George Washington University.
Previously, she served as Director of the Center for Cancer at Children's Research Institute, Director at The Foundation For The Accreditation of Cellular Therapy, Director of Translational Research & Innovation at GW Cancer Center, and President of the International Society for Cellular Therapy.
She also worked as a Professor at Baylor College of Medicine.
Dr. Bollard obtained her doctorate degree from Otago Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CABALETTA BIO, INC.
0,00% | 03/06/2024 | 1 000 ( 0,00% ) | 7 480 $ | 30/06/2024 |
Postes actifs de Catherine Bollard
| Sociétés | Poste | Début |
|---|---|---|
| CABALETTA BIO, INC. | Directeur/Membre du Conseil | 02/04/2019 |
Children's National Hospital (District of Columbia)
 Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Corporate Officer/Principal | 01/01/2013 |
| George Washington University | Corporate Officer/Principal | 01/01/2013 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | 01/01/2023 |
Anciens postes connus de Catherine Bollard
| Sociétés | Poste | Fin |
|---|---|---|
| Baylor College of Medicine | Corporate Officer/Principal | 01/01/2013 |
Mana Therapeutics, Inc.
 Mana Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mana Therapeutics, Inc. provides clinical cell immune therapies that can eliminate cancer cells. The company was founded by Catherine Bollard, Patrick Hanley, C. Russell Y. Cruz and Marc Cohen and is headquartered in Arlington, VA. | Fondateur | - |
| The Foundation For The Accreditation of Cellular Therapy | Directeur/Membre du Conseil | - |
International Society for Cellular Therapy
 International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | President | - |
| GW Cancer Center | Corporate Officer/Principal | - |
Formation de Catherine Bollard
| Otago Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CABALETTA BIO, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| Children's Research Institute, Inc. | |
Children's National Hospital (District of Columbia)
Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Health Services |
| GW Cancer Center | |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | Commercial Services |
| The Foundation For The Accreditation of Cellular Therapy | |
Mana Therapeutics, Inc.
Mana Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mana Therapeutics, Inc. provides clinical cell immune therapies that can eliminate cancer cells. The company was founded by Catherine Bollard, Patrick Hanley, C. Russell Y. Cruz and Marc Cohen and is headquartered in Arlington, VA. | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
